These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 12406506)

  • 1. Inhibition of host kinase activity altered by the LMP2A signalosome-a therapeutic target for Epstein-Barr virus latency and associated disease.
    Cooper L; Longnecker R
    Antiviral Res; 2002 Dec; 56(3):219-31. PubMed ID: 12406506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The LMP2A signalosome--a therapeutic target for Epstein-Barr virus latency and associated disease.
    Portis T; Cooper L; Dennis P; Longnecker R
    Front Biosci; 2002 Feb; 7():d414-26. PubMed ID: 11815296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epstein-Barr virus latent membrane protein 2A (LMP2A) employs the SLP-65 signaling module.
    Engels N; Merchant M; Pappu R; Chan AC; Longnecker R; Wienands J
    J Exp Med; 2001 Aug; 194(3):255-64. PubMed ID: 11489945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein-Barr Virus Latent Membrane Protein 2A (LMP2A) enhances IL-10 production through the activation of Bruton's tyrosine kinase and STAT3.
    Incrocci R; Barse L; Stone A; Vagvala S; Montesano M; Subramaniam V; Swanson-Mungerson M
    Virology; 2017 Jan; 500():96-102. PubMed ID: 27792904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus Latent Membrane Protein 2A (LMP2A)-mediated changes in Fas expression and Fas-dependent apoptosis: Role of Lyn/Syk activation.
    Incrocci R; Hussain S; Stone A; Bieging K; Alt LA; Fay MJ; Swanson-Mungerson M
    Cell Immunol; 2015 Oct; 297(2):108-19. PubMed ID: 26255694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Latent membrane protein 2A of Epstein-Barr virus binds WW domain E3 protein-ubiquitin ligases that ubiquitinate B-cell tyrosine kinases.
    Winberg G; Matskova L; Chen F; Plant P; Rotin D; Gish G; Ingham R; Ernberg I; Pawson T
    Mol Cell Biol; 2000 Nov; 20(22):8526-35. PubMed ID: 11046148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Syk-induced phosphatidylinositol-3-kinase activation in Epstein-Barr virus posttransplant lymphoproliferative disorder.
    Hatton O; Lambert SL; Phillips LK; Vaysberg M; Natkunam Y; Esquivel CO; Krams SM; Martinez OM
    Am J Transplant; 2013 Apr; 13(4):883-890. PubMed ID: 23398911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The LMP2A protein of Epstein-Barr virus regulates phosphorylation of ITSN1 and Shb adaptors by tyrosine kinases.
    Dergai O; Dergai M; Skrypkina I; Matskova L; Tsyba L; Gudkova D; Rynditch A
    Cell Signal; 2013 Jan; 25(1):33-40. PubMed ID: 22975684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway.
    Portis T; Longnecker R
    Oncogene; 2004 Nov; 23(53):8619-28. PubMed ID: 15361852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The c-Cbl proto-oncoprotein downregulates EBV LMP2A signaling.
    Ikeda M; Longnecker R
    Virology; 2009 Mar; 385(1):183-91. PubMed ID: 19081591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spleen Tyrosine Kinase Inhibitor TAK-659 Prevents Splenomegaly and Tumor Development in a Murine Model of Epstein-Barr Virus-Associated Lymphoma.
    Cen O; Kannan K; Huck Sappal J; Yu J; Zhang M; Arikan M; Ucur A; Ustek D; Cen Y; Gordon L; Longnecker R
    mSphere; 2018 Aug; 3(4):. PubMed ID: 30135222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epstein-Barr virus latent membrane protein 2A mediates transformation through constitutive activation of the Ras/PI3-K/Akt Pathway.
    Fukuda M; Longnecker R
    J Virol; 2007 Sep; 81(17):9299-306. PubMed ID: 17582000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus latent membrane protein-2A induces ITAM/Syk- and Akt-dependent epithelial migration through αv-integrin membrane translocation.
    Fotheringham JA; Coalson NE; Raab-Traub N
    J Virol; 2012 Oct; 86(19):10308-20. PubMed ID: 22837212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Src kinase and Syk activation initiate PI3K signaling by a chimeric latent membrane protein 1 in Epstein-Barr virus (EBV)+ B cell lymphomas.
    Hatton O; Lambert SL; Krams SM; Martinez OM
    PLoS One; 2012; 7(8):e42610. PubMed ID: 22880054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Syk activation of phosphatidylinositol 3-kinase/Akt prevents HtrA2-dependent loss of X-linked inhibitor of apoptosis protein (XIAP) to promote survival of Epstein-Barr virus+ (EBV+) B cell lymphomas.
    Hatton O; Phillips LK; Vaysberg M; Hurwich J; Krams SM; Martinez OM
    J Biol Chem; 2011 Oct; 286(43):37368-78. PubMed ID: 21908615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The signaling pathways of Epstein-Barr virus-encoded latent membrane protein 2A (LMP2A) in latency and cancer.
    Pang MF; Lin KW; Peh SC
    Cell Mol Biol Lett; 2009; 14(2):222-47. PubMed ID: 19082921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Epstein-Barr virus latent membrane protein 2A PY motif recruits WW domain-containing ubiquitin-protein ligases.
    Ikeda M; Ikeda A; Longan LC; Longnecker R
    Virology; 2000 Mar; 268(1):178-91. PubMed ID: 10683340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LMP2A survival and developmental signals are transmitted through Btk-dependent and Btk-independent pathways.
    Merchant M; Longnecker R
    Virology; 2001 Dec; 291(1):46-54. PubMed ID: 11878875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine 112 of latent membrane protein 2A is essential for protein tyrosine kinase loading and regulation of Epstein-Barr virus latency.
    Fruehling S; Swart R; Dolwick KM; Kremmer E; Longnecker R
    J Virol; 1998 Oct; 72(10):7796-806. PubMed ID: 9733815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr virus LMP2A reduces hyperactivation induced by LMP1 to restore normal B cell phenotype in transgenic mice.
    Vrazo AC; Chauchard M; Raab-Traub N; Longnecker R
    PLoS Pathog; 2012; 8(4):e1002662. PubMed ID: 22536156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.